NASDAQ · OTLK
Healthcare · Biotechnology
$0.67
Down-$0.02 (-3.51%)
Updated Sep 8, 2026, 5:54 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OTLK closed at $0.67 after 20 trading sessions, down 42.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.6599 | $0.6962 | $0.6451 | $0.6665 | 6.4M |
| Sep 3, 2026 | $0.6217 | $0.6652 | $0.6174 | $0.649 | 6.64M |
| Sep 2, 2026 | $0.62 | $0.64 | $0.6043 | $0.6263 | 4.61M |
| Sep 1, 2026 | $0.63 | $0.6408 | $0.6145 | $0.6231 | 3.58M |
| Aug 31, 2026 | $0.631 | $0.664 | $0.6276 | $0.6334 | 6.43M |
| Aug 28, 2026 | $0.65 | $0.6586 | $0.6191 | $0.6449 | 9.49M |
| Aug 27, 2026 | $0.643 | $0.675 | $0.6355 | $0.6411 | 6.85M |
| Aug 26, 2026 | $0.64 | $0.6589 | $0.6231 | $0.6233 | 6.06M |
| Aug 25, 2026 | $0.615 | $0.6847 | $0.6115 | $0.64 | 15.95M |
| Aug 24, 2026 | $0.6223 | $0.6405 | $0.59 | $0.609 | 14.8M |
| Aug 21, 2026 | $0.6759 | $0.706 | $0.64 | $0.6472 | 11.5M |
| Aug 20, 2026 | $0.6901 | $0.716 | $0.6647 | $0.6763 | 8.67M |
| Aug 19, 2026 | $0.7078 | $0.7181 | $0.6705 | $0.6901 | 20.76M |
| Aug 18, 2026 | $0.6722 | $0.7039 | $0.602 | $0.70 | 41.04M |
| Aug 17, 2026 | $0.7954 | $0.7975 | $0.67 | $0.6722 | 80.66M |
| Aug 14, 2026 | $0.8438 | $0.8438 | $0.712 | $0.7564 | 104.62M |
| Aug 13, 2026 | $0.769 | $0.8918 | $0.7602 | $0.8888 | 82.39M |
| Aug 12, 2026 | $1.12 | $1.18 | $1.07 | $1.10 | 8.07M |
| Aug 11, 2026 | $1.15 | $1.1584 | $1.09 | $1.13 | 6.09M |
| Aug 10, 2026 | $1.00 | $1.18 | $0.995 | $1.15 | 10.31M |
The latest Smart Investors Daily articles mentioning OTLK.
OTLK research
Company profile and research snapshot.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
| May 18, 2026 | BTIG | Neutral | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
Benzinga · Feb 19, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service
Benzinga · Feb 18, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OTLK.
